LRP1 and neoplasm: A previous study showed that liposomal therapy targeting macrophage LRP1 effectively suppresses the crosstalk between tumor metabolism and immune evasion via glycolysis inhibition and immune normalization, resulting in reduced lactic acid production and switching TAMs to an anti-tumor phenotype (34).